Prostate cancer: PSA as an intermediate end point in clinical trials.
Attard
Gerhardt
G
de Bono
Johann S
JS
D015415:Biomarkers / Q000097:blood; D017326:Clinical Trials, Phase III as Topic / Q000379:methods; D023381:Endpoint Determination / Q000379:methods; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000175:diagnosis
D015415:Biomarkers; D017430:Prostate-Specific Antigen